Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. - Wikidata - awgldk - TriplyDB

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

http://www.wikidata.org/entity/Q35992243

about

Evaluation of Gene Therapy as an Intervention Strategy to Treat Brain Injury from Stroke Previous and Recent Evidence of Endovascular Therapy in Acute Ischemic Stroke Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset Cell-based therapy for ischemic stroke Evolution of endovascular mechanical thrombectomy for acute ischemic stroke.NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study): Randomized Controlled Contrast-Enhanced Sonothrombolysis in an Unselected Acute Ischemic Stroke Population.A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS).Advanced neuroimaging to guide acute stroke therapy.Intravenous Tissue Plasminogen Activator Can Be Safely Given without Complete Blood Count Results Back.Intravenous fibrinolysis eligibility: a survey of stroke clinicians' practice patterns and review of the literature.Blood pressure management in stroke: Five new things.Acute stroke reperfusion therapy trends in the expanded treatment window era.Factors Associated with Early Hospital Arrival in Patients with Acute Ischemic Stroke.Preliminary experience with air transfer of patients for rescue endovascular therapy after failure of intravenous tissue plasminogen activator.Temporal trends in acute stroke management.Impact of Day of the Week and Time of Arrival on Ischemic Stroke Management.Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tPA for Acute Ischemic Stroke.Endovascular therapy after intravenous t-PA versus t-PA alone for stroke The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)Analysis of tissue plasminogen activator eligibility by sex in the Greater Cincinnati/Northern Kentucky Stroke Study Intra-arterial treatment of acute ischemic stroke: the continued evolution.Thrombolysis and reperfusion: advanced understanding of early management strategies in acute ischemic stroke.Interventional management of acute ischemic stroke: a systematic review.Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications.Endovascular thrombectomy for the treatment of acute ischemic stroke.History, Evolution, and Importance of Emergency Endovascular Treatment of Acute Ischemic Stroke.Predictors of prognosis and treatment outcome in central retinal artery occlusion: local intra-arterial fibrinolysis vs. conservative treatment.Sequential endovascular thrombectomy approach (SETA) to acute ischemic stroke: preliminary single-centre results and cost analysis.Impact of hyperlipidemia and atrial fibrillation on the efficacy of endovascular treatment for acute ischemic stroke: a meta-analysis.Correlation of clot imaging with endovascular recanalization in internal carotid artery terminus occlusion.Clinical Results of the Intra-Arterial Thrombolysis with Stent Retriever Device Weather Perfusion Diffusion Mismatching and Intravenous Tissue Plasminogen Activator Administration.Contrast-enhanced sonothrombolysis in acute ischemic stroke patients without intracranial large-vessel occlusion.Clinical results of intraarterial thrombolysis according to tPA administration and perfusion/diffusion mismatching.Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?Early CT perfusion mismatch in acute stroke is not time-dependent but relies on collateralization grade.Fate of the penumbra after mechanical thrombectomy.Comparison of stent retriever and intra-arterial fibrinolysis in patients with acute ischaemic stroke.An Overview of Meta-Analyses of Endovascular Bridging Therapies for Acute Ischemic Stroke.

P2860

Q26744103-46A8CF3D-F89B-4B43-A6B8-929CA11594C5 Q26782864-D00AA2FB-E7D0-4BD4-A04E-A42B1ABE057F Q26796477-ACE4B418-0BE1-4897-80C5-E68B986D397F Q26827499-CC6B117F-F000-4088-B489-CD512361DD1D Q30301291-76579F44-8FAA-40F6-BCB3-4EA7307AF590 Q30363884-227A7032-0778-45F1-8AC7-E3D83F8C07F6 Q30407045-5784F6AE-86C8-4C16-AB92-EB5A98DC6ABD Q30570153-08452B29-FE6F-483D-904E-E9CAE941A889 Q33424165-B5DC482E-AD6A-464C-80B2-528FA372F8A2 Q34150539-4985C0FC-2AC1-44D9-9B26-2DF50CB4DB13 Q34335858-53F8DDB0-D827-426D-80D0-64A388CFFAD5 Q35178825-75D0664B-0492-4B94-A43A-1D4ACDD26F0A Q35698461-089493D7-A1F0-444B-8B24-85DA36A7D2DC Q35943436-4547CE05-7112-45B4-AF4B-2F19B78687BA Q36100790-8574F8F8-3ACE-49B9-A434-33D6FA0FF26C Q36249194-3CD27B4D-4B40-473D-9137-3B44CCD88D8B Q36435952-AC113203-8891-45B3-B8E4-3D4041C47CF4 Q36837191-93A18C0C-80D6-4D45-A575-6E6A44BF0E39 Q37320480-CF3D59B4-9200-4D97-B0DF-277A1EC4C78A Q37634025-5ECCCC54-CF30-4E0B-B3A1-E759EF73093C Q38176523-063FDEC3-5BAD-476C-AABC-1BAD05F6AB46 Q38198740-8841A1FA-B6E8-4FC3-ADCE-FC5D7D5A2FEA Q38219583-F05292D5-BD8E-4055-8F92-ED85FC50132F Q38225341-AFA568AF-B0A6-4697-B58B-892F9BD24045 Q38646289-FF5CD84C-84B8-4EC6-B13B-FC46302B7262 Q38791820-C3CE4A56-B5EE-4E38-A317-28F81B390388 Q40562643-5837EA98-D363-4C2A-BE73-B8D8DE0296A7 Q41478522-E0FC698D-A40C-431B-817F-579104C36F20 Q42700714-105E3E3E-F032-4328-A1D7-4427CAE4147F Q46661881-302CE417-C496-42AC-9F58-A09724A95E16 Q48129050-7D8D6551-DDBC-4C63-A6FD-E7F7CB41E268 Q48131541-F15A9211-79B6-4FFC-B135-8D6BA8C153B0 Q48377594-88E48E32-3726-4027-9B47-7165E123AE8A Q48671267-2B13A148-3E85-4052-A4CE-08867957797D Q48968366-874C53CF-0DCE-4E24-B7FC-06CFA171B38E Q53084719-C9C18924-143E-4B51-B86B-C7C8E3525A34 Q53602674-073A4D24-4918-44DF-A538-B90E04C8D37D Q55030717-44A1ECDA-7C57-4798-B309-4C1B4970454F

P2860

Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.

http://www.wikidata.org/entity/Q35992243

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@ast

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@en

type

label

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@ast

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@en

prefLabel

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@ast

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@en

P1433

Q35992243-C15341DD-E1CA-4FF7-B798-0F95CE6EB0C5

P1476

Q35992243-3A730EE9-EC78-4E39-9E62-6957AC54CA4E

P2093

Q35992243-02942820-DA45-4655-9A63-BAE7B5132D6E

Q35992243-177E9537-47E2-406F-8DD9-86DE22D98B1C

Q35992243-464785EB-02D1-4A40-946F-3F963AB04E68

Q35992243-81CA4F06-A7E2-42CA-A6B1-C433571A33B8

Q35992243-B1243011-7F57-405A-9C11-E3792EDB1AE5

Q35992243-B9F58BC7-741E-4403-86CB-152494EC8EB1

Q35992243-C4C0B222-5340-4488-B377-1CF29F179D2C

Q35992243-E0CC5BB2-33D8-4314-9A6A-38D28FB0BB6D

Q35992243-E2E1CE26-166C-4FA8-9A96-F52DD7F80589

Q35992243-EAF85186-08E2-4C46-B33C-9813EEA295EA

P2860

Q35992243-093BA73A-93A5-42D0-8E31-4EE7EDF69F0F

Q35992243-0A1D9A4E-338F-4622-B2D6-F5F9F4CA0511

Q35992243-18FD5C65-53EF-45E5-91B8-115B67DE2193

Q35992243-1EDE4F3B-D27E-45E2-805A-4C302F099BEB

Q35992243-2957353D-F237-4689-B6E7-959E63AFAEA6

Q35992243-2E03B209-8A55-47A3-85F0-5140CCAD742A

Q35992243-352EC79D-E856-4832-9C22-14A770206562

Q35992243-41F3044E-7BFD-4F26-A287-BD21CD249570

Q35992243-49513CCE-CB8E-4CB5-84C2-CC3B90CA4DAC

Q35992243-541AAAF0-9BA3-446A-9407-A477AE993BE5

P304

Q35992243-A4FEF21B-B2AD-4D03-BF1E-778F07992986

P31

Q35992243-7E1B7FD6-2D30-482C-8ED6-54B8F536B9ED

P356

Q35992243-8454C07B-2B23-4473-B503-C01AA58BE84A

P407

Q35992243-7A26321D-A5FF-403E-903F-3134FB8D2AC3

P433

Q35992243-4A4491BD-8D43-4D17-8B8A-17270A4FE5B2

P478

Q35992243-CE5DAC99-AEF3-4768-8EBD-A74645B1026A

P50

Q35992243-D44AD946-3734-4725-88A2-7211F9368004

P577

Q35992243-EDC837B7-3975-4CD9-B85E-F0B5A872AF2E

P698

Q35992243-60489F14-B560-4ADD-8E9A-B606F8B89F2F

P932

Q35992243-97DE2C12-65C3-41E4-8B84-1D6E773D7C6F

P356

STROKEAHA.111.645986

P1433

P1476

Eligibility for Intravenous Re ...... troke Study (ECASS) III Trial.

@en

P2093

Charles J Moomaw

http://www.w3.org/2001/XMLSchema#string

Daniel Woo

http://www.w3.org/2001/XMLSchema#string

Dawn O Kleindorfer

http://www.w3.org/2001/XMLSchema#string

Felipe de Los Ríos la Rosa

http://www.w3.org/2001/XMLSchema#string

Jane Khoury

http://www.w3.org/2001/XMLSchema#string

Kathleen Alwell

http://www.w3.org/2001/XMLSchema#string

Matthew L Flaherty

http://www.w3.org/2001/XMLSchema#string

Opeolu Adeoye

http://www.w3.org/2001/XMLSchema#string

Pooja Khatri

http://www.w3.org/2001/XMLSchema#string

Simona Ferioli

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Early Management of Adults With Ischemic Stroke

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful?

Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale.

Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

Emergency medical services use by stroke patients: a population-based study.

Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial

Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment.

P304

1591-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.111.645986

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Brett M. Kissela

P577

2012-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22442174

http://www.w3.org/2001/XMLSchema#string

P932

3361593

http://www.w3.org/2001/XMLSchema#string